BioSpace News Archive

Job Trends

Top 10 Most Expensive Drugs on the Market

Prescription drug watchdog GoodRx compiled a list of the 10 most expensive drugs on the market. Read further to know more about which drugs are on the list.

March 9, 2021
·
2 min read
·
Alex Keown
Electrophysiology Market: Top 8 trends boosting the industry demand through 2027

Driven by the growing focus toward the management of cardiac arrhythmias and the rising acclaim for telemedicine in the wake of the COVID-19 pandemic, the demand for noninvasive and invasive electrophysiology procedures is expected to soar rapidly throughout the globe.

March 9, 2021
·
7 min read
Job Trends

COVID-19 Vaccine Makers Top List of 2021’s Most Innovative Biotechs

In a list of the most innovative vaccine makers in 2021, Fast Company has outlined 10 biotech companies that continue to revolutionize the drug-discovery landscape.

March 9, 2021
·
4 min read
·
Brandon May
Drug Development

Novartis’ Autoimmune Drug Not Up for the Challenge in Phase III Cancer Trial

The drug was being evaluated in 237 adults with locally advanced or metastatic non-small cell lung cancer whose disease progressed while on or after previous platinum-based chemotherapy and checkpoint inhibitor immunotherapy.

March 9, 2021
·
3 min read
·
Mark Terry
Business

Promoting Diversity & Inclusion Through an Ethos of Cultural and Emotional Intelligence

Despite a historic push for greater diversity and inclusion (D&I), a significant disconnect prevails between good intentions and actual lived experiences.

March 9, 2021
·
6 min read
·
Heather McKenzie
CARB-X Places $22 Million Bet on Affinivax Staph Vaccine

Less than two months after bacterial vaccine company Affinivax’s Series C financing, the company is getting a $22 million boost from infectious disease consortium CARB-X to push forward a vaccine for tough-to-treat preclinical Staphylococcus aureus

March 9, 2021
·
2 min read
·
Mark Zipkin
Potential Blockbuster Drugs for 2021 – Alzheimer’s, Prostate Cancer and More

Clarivate published its annual “Drugs to Watch” list, and cited four drugs that it expects to be blockbusters—projected to bring in $1 billion in sales annually.

March 9, 2021
·
5 min read
·
Mark Terry
Business

Takeda Inks Deal to Go After Solid Tumors with Maverick T-Cell Engager Technology

The pair’s lead candidate, TAK-186 (formerly MVC-101), a first-in-class conditionally active T-cell engager, has recently entered the clinic in a Phase I/II study for the treatment of EGFR-expressing solid tumors such as those found in head and neck cancers.

March 9, 2021
·
3 min read
·
Heather McKenzie
Drug Development

2021 Biopharma Update on the Novel Coronavirus: March 9

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 9, 2021.

March 9, 2021
·
5 min read
·
BioSpace Editorial Staff
Business

Industry Veterans Jump Ship in Favor of Smaller Biotechs

It didn’t take long for Jason Campagna to find a new role after departing Intercept Pharmaceuticals last month. Campagna will take on the role of chief medical officer for Q32 Bio.

March 9, 2021
·
3 min read
·
Alex Keown